Skip to content
TrustList
CureDuchenne Ventures logo
Investor

CureDuchenne Ventures

Impact investment fund financing treatments for Duchenne muscular dystrophy, run by the CureDuchenne charity

CureDuchenne Ventures cover

About CureDuchenne Ventures

A venture fund that turns donations into Duchenne research

CureDuchenne Ventures is the investment arm of CureDuchenne, a national nonprofit working to cure Duchenne muscular dystrophy, which it describes as the most common and lethal form of muscular dystrophy. The fund was formed in 2014, after the sale of an early equity stake in Prosensa to BioMarin Pharmaceuticals, and it is run as an impact fund: donor money goes into companies and research groups developing Duchenne treatments, with a stated aim of funding a cure for the whole community.

How the impact model works

The firm describes a three-step model of finding, funding and fostering promising science. Through that model it can give grants to academic groups as well as take equity positions in biotech and pharmaceutical companies. Its early money is meant to make Duchenne science look credible enough for venture capital firms, biotech companies and drug makers to invest later. When an equity position pays off, proceeds are recycled: the site speaks of reinvesting 90% of proceeds from equity positions in research, and elsewhere says all investment returns go back into research, resources and support for families, so that the fund can sustain itself.

What the portfolio covers

The site reports 12 projects with three successful exits. The therapies span several approaches:

  • Gene editing and gene therapy, including work on viral delivery, non-viral delivery platforms and ways of shielding therapy vectors from the immune system.
  • Exon skipping, using oligonucleotide and peptide-conjugated approaches meant to reach skeletal, cardiac and smooth muscle.
  • Drugs that target other parts of the disease, such as anti-inflammatory compounds with fewer side effects than current steroids, treatments for muscle metabolism, bone loss and fibrosis, and stop-codon read-through.
  • Cardiac cell therapy.

Tools around the drugs

The fund has also backed supporting work: a project to improve the design of Duchenne clinical trials, a newborn screening effort, a specialty prescribing application for patients, and a contract research organization focused on neuromuscular disease. Earlier backing helped Sarepta reach the first approval of a Duchenne drug while it was on clinical hold, according to the older site. Past exits include Prosensa, Bamboo Therapeutics, which went to Pfizer in 2016, and Exonics Therapeutics, whose acquisition by Vertex the fund helped to assist.

What it looks for

Beyond the standard therapies, the fund says it also looks for novel technologies and platform approaches that overcome the limits of existing programs in development.

TrustList summary

The fund serves as the investing wing of CureDuchenne, a national charity focused on curing Duchenne muscular dystrophy. It was formed in 2014 after a successful exit from an earlier equity investment.

Products and services

  • Impact fund: puts donor funds into companies developing Duchenne treatments.
  • Gene and exon-skipping therapies: investments include dystrophin-restoring approaches and other disease mechanisms.
  • Platform technologies: it also looks for new platforms that overcome limits in existing therapies.
  • Early funding: its early backing is meant to attract later investment from venture capital, biotech and pharmaceutical firms.
  • Reinvestment: 90% of earnings go back into Duchenne research.

Clients

Biotech companies and research projects working on Duchenne, such as Exonics Therapeutics, Capricor Therapeutics, Dyne Therapeutics and Avidity.

Key facts

  • Formed: 2014
  • Parent: CureDuchenne, a national nonprofit
  • Earnings reinvested: 90%

Summary written by TrustList from the business's own published information, Nov 2026.

Categories & features

CureDuchenne Ventures rankings

CureDuchenne Ventures is ranked on 1 TrustList ranking at #14.

Every ranking orders its listings by their reviews, how complete the profile is and the Trust Score. CureDuchenne Ventures has no reviews yet and 3 of the 10 profile details we look for. Where no listing on a page has been reviewed, the order follows the profiles alone.

Investor · 1 ranking

As of 2026-11-16. Organic ranks only; sponsored placements are never ranks. How TrustList ranks

What the business tells TrustList

Founded
2014 (12 years) evidence sent

Ask TrustList to introduce you to CureDuchenne Ventures

TrustList reads every request before passing it on, and sends it only where the funder's stage and focus look like a fit. We do not charge for introductions, and we cannot promise a reply.

Protected by reCAPTCHA - Google Privacy Policy and Terms apply.

Reviews

Write the first review of CureDuchenne Ventures

Used it? Your experience helps other buyers decide.

Write a review

Questions & answers

No questions yet. Be the first to ask about CureDuchenne Ventures.

CureDuchenne Ventures alternatives

Similar listings buyers compare against this one.

Company studio and early-stage investor that designs, builds and funds startups with hands-on founder support

Chicago-based accelerator for technology companies serving the real estate industry

Desktop office software with a word processor, spreadsheet, presentations and PDF tools for individuals

Semiconductor and display equipment maker that also invests in startups through venture and research programmes

Medical device manufacturer making implants and therapies for heart, cancer and spinal conditions

Global startup accelerator and early-stage investor running city and sector programmes for founders

Early-stage investor backing frontier technology companies, supported by a collective of global entrepreneurs

Web3 venture firm combining investment, engineering and liquidity support for early-stage crypto projects